Armistice Capital, LLC Bio Xcel Therapeutics, Inc. Transaction History
Armistice Capital, LLC
- $7.69 Billion
- Q2 2024
A detailed history of Armistice Capital, LLC transactions in Bio Xcel Therapeutics, Inc. stock. As of the latest transaction made, Armistice Capital, LLC holds 2,987,000 shares of BTAI stock, worth $1.79 Million. This represents 0.05% of its overall portfolio holdings.
Number of Shares
2,987,000
Previous 370,973
705.18%
Holding current value
$1.79 Million
Previous $1.05 Million
265.49%
% of portfolio
0.05%
Previous 0.01%
Shares
2 transactions
Others Institutions Holding BTAI
# of Institutions
78Shares Held
7.26MCall Options Held
101KPut Options Held
205K-
Vanguard Group Inc Valley Forge, PA970KShares$582,2580.0% of portfolio
-
Black Rock Inc. New York, NY441KShares$264,4110.0% of portfolio
-
Geode Capital Management, LLC Boston, MA267KShares$160,0310.0% of portfolio
-
Charles Schwab Investment Management Inc San Francisco, CA204KShares$122,1690.0% of portfolio
-
Northern Trust Corp Chicago, IL195KShares$116,9710.0% of portfolio
About BioXcel Therapeutics, Inc.
- Ticker BTAI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,022,500
- Market Cap $16.8M
- Description
- BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and prop...